Mindpath Health Psychiatrists & Therapists - Modesto
1700 Standiford Avenue, Suite 355, Modesto
4.8(202 Google reviews)
United States
4 listed treatment centers serving Modesto and the surrounding area.
1700 Standiford Avenue, Suite 355, Modesto
4.8(202 Google reviews)
5222 Pirrone Court, Suite 101A, Salida
4.6(46 Google reviews)
For people in Modesto considering SPRAVATO®, the cost depends on insurance benefits, the treatment setting, and the prescribed visit schedule. Ask for an estimate that separates the medication from the supervised treatment and monitoring services: both may be billed, and your plan may process them differently.
Prior authorization is common. A center may need to submit records of earlier antidepressant trials, including which medications you took and how you responded. Ask what records are needed, who will request them, and whether authorization must be renewed during treatment. An initial authorization is not a promise that every future visit will be covered.
Medicare coverage may fall under Part B or Part D, depending on the plan and setting. California Medicaid coverage also depends on the plan and setting. Do not assume a listed center accepts either program; confirm with both the office and your insurer.
Manufacturer savings programs exist for some eligible commercially insured patients, but not for patients using government insurance. Ask about current eligibility rules and which charges a program may help with; medication assistance may not address every visit-related expense.
Before starting, ask the center and insurer:
Also budget for transportation and time away from work throughout treatment.
SPRAVATO® treatment requires repeated visits to a REMS-certified healthcare setting. You administer the nasal spray yourself under direct observation of a healthcare provider; it is never sent home for you to use. A directory listing alone does not establish certification, so ask the center to confirm its current REMS status before scheduling.
For treatment-resistant depression, the typical labeled schedule starts with twice-weekly visits during weeks 1–4, followed by weekly visits during weeks 5–8. Maintenance may be weekly or every two weeks. Your prescriber determines your schedule, so avoid assuming that appointments will become less frequent on a fixed date.
Plan for at least two hours of monitoring after each dose, plus check-in and other care. Staff monitor for sedation, dissociation, breathing problems, and increased blood pressure. Ask how much total time to reserve and whether your appointment could run longer.
You need someone else to take you home. Do not drive or operate machinery until the next day after a restful sleep. Arrange a reliable driver for each visit, discuss acceptable ride arrangements with the center, and have a backup plan. When planning time off work, account for the visit, transportation, and restrictions on driving or operating equipment afterward.
Modesto has listed treatment options, but availability and certification need confirmation. If no Modesto listing is available or suitable when you search, consider the listing in Salida or broaden your search to Sacramento. Confirm appointment availability, REMS certification, insurance participation, and a workable return-ride plan before committing to another location.
Use the Modesto listings as a starting point, then contact the office directly. Ask whether it is currently SPRAVATO® REMS-certified and accepting new patients. Certification is not confirmed in the supplied listings. If local options do not work for you, you can also investigate listed options in Salida or Sacramento, checking certification, insurance participation, and transportation arrangements.
Spravato is FDA-approved for adults with treatment-resistant depression, either alone or with an oral antidepressant. It is also approved for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, together with an oral antidepressant. It is not approved for children. A clinician must review your history and safety considerations; a diagnosis alone does not guarantee eligibility.
Coverage depends on your plan and the treatment setting. Prior authorization and documentation of earlier antidepressant trials are common requirements. Ask your insurer about both the medication and the supervised monitoring visit, and confirm the center's participation separately. Medicare and California Medicaid may cover treatment depending on the plan and setting, but a directory listing does not establish coverage or acceptance.
You self-administer the nasal spray at a REMS-certified healthcare setting under direct observation of a healthcare provider. After the dose, staff monitor you for at least two hours, including checks for sedation, dissociation, breathing problems, and blood pressure increases. Allow extra time for other care. Someone else must take you home; driving is prohibited until the next day after a restful sleep.
Ask about sedation, dissociation—a feeling of disconnection from yourself or your surroundings—respiratory depression, and blood pressure increases. Spravato carries boxed warnings for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviors. It is a Schedule III controlled substance. Discuss your health history and medications with the clinician, and tell staff immediately if you feel unwell during monitoring.
No. Spravato has not been shown to prevent suicide or reduce suicidal thoughts or behavior, and it does not replace hospitalization when clinically warranted. Do not wait for a treatment appointment if you need urgent help. In an emergency, call or text 988 or call 911. A clinician can discuss treatment options after immediate safety needs are addressed.
Approved uses, nearby treatment centers, and medically sourced patient guides.